昆藥集團(600422.SH):孫公司簽署普瑞巴林口服溶液上市許可受讓協議
格隆匯5月27日丨昆藥集團(600422.SH)公佈,近日,公司全資孫公司貝克諾頓(浙江)製藥有限公司(以下簡稱“貝克諾頓(浙江)”或“甲方”)與杭州和澤坤元藥業有限公司(以下簡稱“和澤坤元”或“乙方”)簽署《普瑞巴林口服溶液技術與權益轉讓協議》,和澤坤元作為轉讓協議項下之協議產品普瑞巴林口服溶液(規格:2%(473ml:9460mg)的知識產權所有人和上市許可持有人,擬將協議產品的相關知識產權及上市許可轉讓給貝克諾頓(浙江),協議轉讓費用為2000萬元人民幣。
普瑞巴林是第二代鈣離子通道調節劑,增強了與α2-δ亞基的親和力,能夠緩解PHN、改善睡眠和情感障礙。產品呈線性藥代動力學特徵,療效可預估,生物利用度≥90%。截止目前,國內已有7家公司普瑞巴林製劑獲批上市,普瑞巴林口服溶液是該分子國內上市的首個口服液產品,填補了臨牀該劑型產品的空白,將為相關疾病的治療提供更多的用藥選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.